Related Experiment Video
Updated: Jun 22, 2025
09:30
Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
3.1K
MaterniCode: New Bioinformatic Pipeline to Detect Fetal Aneuploidies and Rearrangements Using Next-Generation
Federico Gabrielli1, Filomena Tiziana Papa1, Fabio Di Pietro1
1Biolab srl, Laboratorio di Genetica molecolare e Genomica 63100, Ascoli Piceno, Italy.
International Journal of Genomics
|July 4, 2024
Summary
MaterniCode, a new bioinformatic pipeline for noninvasive prenatal testing (NIPT), accurately determines fetal sex and detects aneuploidies using Ion Torrent sequencing. This cost-effective tool enhances prenatal diagnostics with high sensitivity and specificity.
Area of Science:
- Genomics and Bioinformatics
- Molecular Diagnostics
- Reproductive Medicine
Background:
- Noninvasive prenatal testing (NIPT) is crucial for early detection of fetal chromosomal abnormalities.
- Existing NIPT methods require optimization for speed, cost-effectiveness, and accuracy.
- Bioinformatic pipelines are essential for analyzing next-generation sequencing data in NIPT.
Purpose of the Study:
- To introduce and evaluate MaterniCode, a novel bioinformatic pipeline for NIPT.
- To assess MaterniCode's performance on the Ion Torrent semiconductor sequencing platform.
- To compare MaterniCode's accuracy against established NIPT solutions.
Main Methods:
- Development and application of two distinct bioinformatic strategies for fetal sex determination.
- Analysis of 1225 maternal blood samples for fetal aneuploidies using MaterniCode.
- Benchmarking MaterniCode's performance against Illumina VeriSeq™ NIPT Solution v2.
Main Results:
- MaterniCode achieved near-perfect accuracy for fetal sex determination via chrY-specific gene analysis.
- An alternative method within MaterniCode demonstrated 100% accuracy for fetal sex determination.
- Both WisecondorX and NIPTeR algorithms within MaterniCode showed 100% sensitivity and specificity for aneuploidy detection, matching industry standards.
- MaterniCode successfully identified complex chromosomal abnormalities, including a 2.4 Mb deletion on chromosome 13 and a 3 Mb duplication on chromosome 2.
Conclusions:
- MaterniCode is an innovative and efficient NIPT tool with excellent sensitivity and specificity.
- The pipeline effectively detects a wide range of complex chromosomal aberrations, including rare variations.
- MaterniCode represents a valuable advancement in prenatal diagnostic technologies, aiding clinical decision-making.
